Tranexamic acid_1197-18-8_DataSheet_MedChemExpress

合集下载

钛酸异丙酯产品安全技术说明书（阿拉丁）

GHS02:易燃物; GHS06:急毒性物质钛酸异丙酯Titanium(IV) isopropoxide99.99%CAS No. 546-68-9EC-编号208-909-64急救措施4.1必要的急救措施描述一般的建议请教医生。

向到现场的医生出示此安全技术说明书。

如果吸入如果吸入,请将患者移到新鲜空气处。

如呼吸停止，进行人工呼吸。

请教医生。

在皮肤接触的情况下用肥皂和大量的水冲洗。

请教医生。

在眼睛接触的情况下用大量水彻底冲洗至少15分钟并请教医生。

如果误服禁止催吐。

切勿给失去知觉者喂食任何东西。

用水漱口。

请教医生。

4.2最重要的症状和影响，急性的和滞后的无数据资料4.3及时的医疗处理和所需的特殊处理的说明和指示无数据资料5消防措施5.1灭火介质火灾特征无数据资料灭火方法及灭火剂干粉干砂不要用水喷射。

5.2源于此物质或混合物的特别的危害无数据资料5.3救火人员的预防如有必要，佩戴自给式呼吸器进行消防作业。

5.4进一步的信息喷水冷却未打开的容器。

6泄露应急处理6.1人员的预防,防护设备和紧急处理程序使用个人防护装备。

避免吸入蒸气、气雾或气体。

保证充分的通风。

消除所有火源。

注意蒸气积累达到可爆炸的浓度，蒸气可蓄积在地面低洼处。

6.2环境预防措施如能确保安全，可采取措施防止进一步的泄漏或溢出。

不要让产品进入下水道。

6.3抑制和清除溢出物的方法和材料围堵溢出物，用非可燃性材料(如砂子、泥土、硅藻土、蛭石)吸收溢出物，将其收集到容器中，根据当地的或国家的规定处理6.4参考其他部分丢弃处理请参阅第13节。

7安全操作与储存7.1安全操作的注意事项避免接触皮肤和眼睛。

避免吸入蒸气或雾滴。

火舌回闪有可能穿过相当长的距离。

容器遇火可能会爆炸切勿靠近火源。

－严禁烟火。

采取措施防止静电积聚。

7.2安全储存的条件,包括任何不兼容性在氩气下操作,避免潮湿。

储存于氩气中使容器保持密闭，储存在干燥通风处。

离子色谱法测定枸橼酸芬太尼原料药和注射液中枸橼酸的含量

China Pharmacy 2017V ol.28No.18中国药房2017年第28卷第18期Δ基金项目：中国医学科学院与健康科技创新工程系统创新团队基金（No.2016-I 2M-3-010）＊主管药师，硕士。

研究方向：药品质量标准。

电话：010-********。

E-mail ：***************.cn#通信作者：主任药师。

研究方向：药品质量标准。

电话：010-********。

E-mail ：****************.cn 枸橼酸芬太尼（Fentanyl citrate ）是人工合成的强效麻醉性镇痛药，为阿片类受体激动药，镇痛作用机制与吗啡相似，作用强度为吗啡的60～80倍；其可用于麻醉前、中、后的镇静与镇痛，以及各种肿瘤疼痛和慢性疼痛的治疗[1]。

枸橼酸（柠檬酸）作为枸橼酸芬太尼中的反离子配基，提高了药物的溶解性、稳定性和生物利用度，检测和控制枸橼酸芬太尼原料药和注射液中枸橼酸的含量对保证其结构均一和质量可靠具有积极意义[1]。

目前用于有机酸分析的方法主要有薄层色谱法（TLC ）[2-3]、气相色谱法（GC ）[4-5]、毛细管电泳法（CE ）[6-7]、高效液相色谱法（HPLC ）[8-11]和离子色谱法（IC ）[12-15]等。

TLC 、GC 和CE 法检测结果不准确，而HPLC 法多采用有机相与一定浓度的缓冲盐溶液洗脱，流动相的制备较为复杂。

IC 法流动相简单，环保无污染；采用在线淋洗液发生器能够简化操作，增强方法重复性；且采用电导或紫外检测器，有较好的选择性和灵敏度[16]。

鉴于此，本课题组采用IC 法建立了测定枸橼酸芬太尼原料药和注射液中枸橼酸含量的方法，以期为其质量控制提供参考。

1材料1.1仪器Thermo Dionex ICS-5000+型IC 仪，包括自循环模式的抑制型电导检测器、EGC-500淋洗液自动发生器、Chromeleon 7.2色谱工作站（美国Thermo Fisher Scientific 公司）；XP 205型十万分之一电子分析天平（瑞士Mettler-Toledo 公司）；Milli-Q Integral 型超纯水器（德国Merck Millipore 公司）。

Roche_Xtreme GeneHP_protocal

0910.06479774001ቢ

The recommended starting concentration is a 3:1. For most cell types, these X-tremeGENE HP DNA Transfection Reagent to DNA ratios provide excellent transfection efficiency. Further optimization may increase transfection efficiency in your particular application. In addition to varying the ratio, other parameters may also be evaluated, such as the amount of transfection complex added. For additional optimization guidelines, see Section 3, Troubleshooting and visit . Plasmid DNA • For best results, accurately determine the plasmid DNA concentration using 260-nm absorption; estimates of DNA by measuring gel band density are not recommended. Determine DNA purity using a 260 nm/280 nm ratio (the optimal ratio is 1.8). • Prepare the plasmid DNA solution using sterile TE (Tris/EDTA) buffer or sterile water at a concentration of 0.1 to 2.0 µg/µl. • Use high quality DNA preparation kits to obtain endotoxin-free DNA. Cell Culture Conditions • Minimize intra- and inter-experimental variance in transfection efficiency using cells that are regularly passaged, proliferating well in a log-growth phase, and plated at a consistent density. • For best results, accurately quantify cell concentration using a hematocytometer or automated system. • Cells must be healthy and free of Mycoplasma. • Cells should have a low passage number to achieve best results. Other Media Additives In some cell types, antimicrobial agents (e.g., antibiotics and fungicides) commonly included in cell-culture media may adversely affect the transfection efficiency of X-tremeGENE HP DNA Transfection Reagent. If possible, exclude additives in initial experiments. Once high-efficiency conditions have been established, these components can be added back while monitoring transfection results. Cell growth and/or transfection efficiency may be affected by variations in serum quality and medium formulations. Verification of Vector Function Optimize transfection conditions using a known positive-control reporter gene construct before transfecting cells with a new vector construct: • Determine transfection efficiency using a reporter gene assay, such as ␤-Gal*, Luciferase*, or SEAP*. • Sequence flanking vector insert regions to verify the integrity of your new construct. 2.2 Transfection Procedure Adherent Cells: Plate cells approximately 24 hours before transfection making sure cells are at the optimal concentration in the appropriate cell culture vessel. Suspension Cells: Plate freshly passaged cells at optimal concentration.

化妆品中抗坏血酸磷酸酯镁等11种原料的检验方法2023年

附件7化妆品中抗坏血酸磷酸酯镁等11种原料的检验方法Determination of L-Ascorbic acid2-phosphate magnesium ester and other ten components incosmetics1范围本方法规定了高效液相色谱法测定化妆品中抗坏血酸磷酸酯镁、抗坏血酸葡糖苷、苯乙基间苯二酚、4-丁基间苯二酚、4-甲氧基水杨酸钾、阿魏酸、烟酰胺、曲酸、3-邻-乙基抗坏血酸、鞣花酸、凝血酸（氨甲环酸）11种成分的含量。

本方法第一部分适用于化妆品水剂类、乳液类、凝胶类、贴面面膜类、膏霜类和粉底类化妆品中抗坏血酸磷酸酯镁、抗坏血酸葡糖苷、苯乙基间苯二酚、4-丁基间苯二酚、4-甲氧基水杨酸钾、阿魏酸、烟酰胺、曲酸、3-邻-乙基抗坏血酸、鞣花酸含量的测定。

本方法第二部分适用于水剂类、乳液类、凝胶类、贴面面膜类、膏霜类化妆品中凝血酸（氨甲环酸）含量的测定。

第一部分化妆品中抗坏血酸磷酸酯镁等10种原料的检测2方法提要样品经甲醇水溶液（或添加少量二氯甲烷促溶解）超声提取后，采用高效液相色谱系统分离，二极管阵列检测器（DAD）检测，根据保留时间定性，峰面积定量，以标准曲线法计算含量。

本方法10种原料的检出限、定量下限及取样量为0.5g时检出浓度和最低定量浓度见表1。

表110种原料的检出限、定量下限、检出浓度和最低定量浓度序号成分检出限（ng）定量下限（ng）检出浓度（μg/g）最低定量浓度（μg/g）1抗坏血酸磷酸酯镁0.4 1.30.8 2.6 2抗坏血酸葡糖苷 1.0 3.1 2.0 6.2 3苯乙基间苯二酚 4.68.79.217.4 44-丁基间苯二酚 2.7 4.9 5.49.8 54-甲氧基水杨酸钾0.4 1.00.8 2.0 6阿魏酸0.5 1.2 1.0 2.4 7烟酰胺 1.0 3.3 2.0 6.6 8曲酸 1.1 2.1 2.2 4.2 93-邻-乙基抗坏血酸 1.4 2.7 2.8 5.4 10鞣花酸 2.7 6.1 5.412.23试剂和材料除另有规定外，本方法所用试剂均为分析纯，水为GB/T6682规定的一级水。

安捷伦产品目录

15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ～ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤優秀的溫控設備讓各個 well 都能保持溫度的穩定七吋的高解析度觸控螢幕讓操作上更為簡便可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題

VERSILOK 254 产品说明书

USA SAFETY DATA SHEET1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATIONProduct name:VERSILOK 254Product Use/Class: Acrylic Adhesive, Part 2 of 2LORD Corporation111 LORD DriveCary, NC 27511-7923 USATelephone: 814 868-3180Non-Transportation Emergency: 814 763-2345Chemtrec 24 Hr Transportation Emergency No.800 424-9300 (Outside Continental U.S. 703 527-3887)EFFECTIVE DATE: 11/18/20202. HAZARDS IDENTIFICATIONGHS CLASSIFICATION:Acute toxicity Inhalation - Dust and MistCategory 4 - 63.1% of the mixture consists of ingredient(s) of unknown toxicity.Reproductive toxicity Category 2Specific target organ systemic toxicity (single exposure) Category 1 Nervous systemSpecific target organ systemic toxicity (repeated exposure) Category 1 Nervous systemSpecific target organ systemic toxicity (repeated exposure) Category 2 Adrenal glandHazardous to the aquatic environment - acute hazard Category 1Hazardous to the aquatic environment - chronic hazard Category 1GHS LABEL ELEMENTS:Symbol(s)Signal WordD ANGERHazard StatementsHarmful if inhaled.Suspected of damaging fertility or the unborn child.Causes damage to organs.(Nervous system)Causes damage to organs through prolonged or repeated exposure.(Nervous system)May cause damage to organs through prolonged or repeated exposure.(Adrenal gland)Very toxic to aquatic life.Very toxic to aquatic life with long lasting effects.Precautionary StatementsPreventionObtain special instructions before use.Do not handle until all safety precautions have been read and understood.Use personal protective equipment as required.Do not breathe dust/fume/gas/mist/vapors/spray.Wash thoroughly after handling.Do not eat, drink or smoke when using this product.Use only outdoors or in a well-ventilated area.Avoid release to the environment.300000001064ResponseCall a POISON CENTER or doctor/physician if you feel unwell.IF exposed: Call a POISON CENTER or doctor/physician.Specific treatment (see supplemental first aid instructions on this label).IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing.Collect spillage.StorageStore locked up.Disposal:Dispose of contents/container in accordance with waste/disposal laws and regulations of your country or particular locality.Other Hazards:This product contains component(s) which have the following warnings; however based on the GHS classification criteria of your country or locale, the product mixture may be outside the respective category(s).Acute: Dermal absorption possible. May cause eye irritation. May cause respiratory tract irritation. May causeheadache and nausea. See Section 11 for additional information. May be harmful if swallowed. Ingestion is not an expected route of entry in industrial or commercial uses.Chronic: Repeated or prolonged skin contact may cause allergic reactions with susceptible persons. Chronicexposure to the tricresyl phosphate in this product may cause adrenal, reproductive and developmental effects based on animal data. See Section 11 for additional information.withheld.FIRST AID - EYE CONTACT: Flush eyes immediately with large amount of water for at least 15 minutes holding eyelids open while flushing. Get prompt medical attention.FIRST AID - SKIN CONTACT: Flush contaminated skin with large amounts of water while removing contaminated clothing. Wash affected skin areas with soap and water. Get medical attention if symptoms occur.FIRST AID - INHALATION: Move person to fresh air. Restore and support continued breathing. If breathing is difficult, give oxygen. Get immediate medical attention.FIRST AID - INGESTION: If swallowed, do not induce vomiting. Call a physician or poison control center immediately for further instructions. Never give anything by mouth if victim is rapidly losing consciousness, unconscious or convulsing.SUITABLE EXTINGUISHING MEDIA: Carbon Dioxide, Dry Chemical, Foam, Water FogUNSUITABLE EXTINGUISHING MEDIA: Not determined for this product.SPECIFIC HAZARDS POSSIBLY ARISING FROM THE CHEMICAL: Keep containers tightly closed. Closed containers may rupture when exposed to extreme heat. Use water spray to keep fire exposed containers cool. During a fire, irritating and/or toxic gases and particulate may be generated by thermal decomposition or combustion.SPECIAL PROTECTIVE EQUIPMENT AND PRECAUTIONS FOR FIRE-FIGHTERS: Wear full firefighting protective clothing, including self-contained breathing apparatus (SCBA). If water is used, fog nozzles are preferable.PERSONAL PRECAUTIONS, PROTECTIVE EQUIPMENT AND EMERGENCY PROCEDURES: Avoid breathing vapors. Avoid contact. Use appropriate respiratory protection for large spills or spills in confined area.ENVIRONMENTAL PRECAUTIONS: Do not contaminate bodies of water, waterways, or ditches, with chemical or used container.METHODS AND MATERIALS FOR CONTAINMENT AND CLEANUP: Notify appropriate authorities if necessary. Avoid contact. Keep non-essential personnel away from spill area. Scoop spilled material into an appropriate container for proper disposal. (If necessary, use inert absorbent material to aid in containing the spill).HANDLING: Keep closure tight and container upright to prevent leakage. Avoid skin and eye contact. Wash thoroughly after handling. Do not handle until all safety precautions have been read and understood.STORAGE: Store only in well-ventilated areas. Keep container closed when not in use.INCOMPATIBILITY: Amines, acids, water, hydroxyl, or active hydrogen compounds.Engineering controls: Sufficient ventilation in pattern and volume should be provided in order to maintain air contaminant levels below recommended exposure limits.PERSONAL PROTECTION MEASURES/EQUIPMENT:RESPIRATORY PROTECTION: Use a NIOSH approved air-purifying organic vapor respirator if occupational limits are exceeded. For emergency situations, confined space use, or other conditions where exposure limits may be greatly exceeded, use an approved air-supplied respirator. For respirator use observe OSHA regulations (29CFR1910.134) or use in accordance with applicable laws and regulations of your country or particular locality.SKIN PROTECTION: Use neoprene, nitrile, or rubber gloves to prevent skin contact.EYE PROTECTION: Use safety eyewear including safety glasses with side shields and chemical goggles where splashing may occur.OTHER PROTECTIVE EQUIPMENT: Use disposable or impervious clothing if work clothing contamination is likely. Remove and wash contaminated clothing before reuse.HYGIENIC PRACTICES: Wash hands before eating, smoking, or using toilet facility. Food or beverages should not be consumed anywhere this product is handled or stored. Wash thoroughly after handling.Typical values, not to be used for specification purposes.ODOR: Epoxy VAPOR PRESSURE: N.D.APPEARANCE: Gray VAPOR DENSITY: Heavier than AirPHYSICAL STATE: Liquid LOWER EXPLOSIVE LIMIT: Not ApplicableUPPER EXPLOSIVE LIMIT: Not ApplicableFLASH POINT:≥ 201 °F, 93 °CSetaflash Closed CupBOILING RANGE: N.A.EVAPORATION RATE: Not Applicable AUTOIGNITION TEMPERATURE:N.D.DENSITY: 1.44 g/cm3 (11.97 lb/gal) DECOMPOSITION TEMPERATURE:N.D. VISCOSITY, DYNAMIC: N.D.ODOR THRESHOLD: N.D.VISCOSITY, KINEMATIC: N.D.SOLUBILITY IN H2O: Insoluble VOLATILE BY WEIGHT: 0.03 %pH: N.A.VOLATILE BY VOLUME: 0.05 %FREEZE POINT: N.D. VOC CALCULATED: 0 lb/gal, 0 g/l0 g/lN.D. METHOD 24: 0.85 lbs/gal COEFFICIENT OF WATER/OILDISTRIBUTION:LEGEND: N.A. - Not Applicable, N.E. - Not Established, N.D. - Not DeterminedHAZARDOUS POLYMERIZATION: Hazardous polymerization will not occur under normal conditions. STABILITY: Product is stable under normal storage conditions.CONDITIONS TO AVOID: High temperatures.INCOMPATIBILITY: Amines, acids, water, hydroxyl, or active hydrogen compounds.HAZARDOUS DECOMPOSITION PRODUCTS: Carbon monoxide, carbon dioxide, aldehydes, Oxides of phosphorusEXPOSURE PATH: Refer to section 2 of this SDS.SYMPTOMS:Refer to section 2 of this SDS.TOXICITY MEASURES:Germ cell mutagenicity: No classification proposedCarcinogenicity: No classification proposedReproductive toxicity: Category 2 - Suspected of damaging fertility or the unborn child.Components contributing to classification: Tricresyl phosphate.TOXICOLOGICAL INFORMATION:Historical data on Tricresyl phosphate (TCP) has shown neurological effects associated with levels of the ortho isomer within TCP. The manufacturer of the TCP in this product has noted on their SDS that the TCP does not exhibit negative neurological effects based on toxicology and epidemiology studies. This LORD product may contain a very small amount of the ortho isomer. However, LORD analytical testing of the raw material containing TCP indicates no ortho isomer present. Also, based on the TCP manufacturer's information, the LORD product content should not exceed225ppm, if present at all.ECOTOXICITY:PERSISTENCE AND DEGRADABILITY:Not determined for this product.BIOACCUMULATIVE: Not determined for this product.MOBILITY IN SOIL: Not determined for this product.OTHER ADVERSE EFFECTS: Not determined for this product.DISPOSAL METHOD: Disposal should be done in accordance with Federal (40CFR Part 261), state and local environmental control regulations. If waste is determined to be hazardous, use licensed hazardous waste transporter and disposal facility.US DOT RoadProper Shipping Name: Environmentally hazardous substances, liquid, n.o.s.Hazard Class: 9SECONDARY HAZARD: NoneUN/NA Number: 3082Packing Group: IIIEmergency Response Guide Number: 171For US DOT non-bulk road shipments this material may be classified as NOT REGULATED. For the most accurate shipping information, refer to your transportation/compliance department regarding changes inpackage size, mode of shipment or other regulatory descriptors.IATA CargoPROPER SHIPPING NAME: Environmentally hazardous substance, liquid, n.o.s.Hazard Class: 9HAZARD CLASS: NoneUN NUMBER: 3082PACKING GROUP: IIIEMS: 9LIMDGPROPER SHIPPING NAME: Environmentally hazardous substance, liquid, n.o.s.Hazard Class: 9HAZARD CLASS: NoneUN NUMBER: 3082PACKING GROUP: IIIEMS: F-AThe listed transportation classification applies to non-bulk shipments. It does not address regulatory variations due to changes in package size, mode of shipment or other regulatory descriptors. For the most accurate shipping information, refer to your transportation/compliance department.U.S. FEDERAL REGULATIONS: AS FOLLOWS:SARA SECTION 313This product contains the following substances subject to the reporting requirements of Section 313 of Title III of the Superfund Amendment and Reauthorization Act of 1986 and 40 CFR part 372.:Chemical Name CAS Number Weight % Less ThanDibenzoyl peroxide94-36-0 5.0%TOXIC SUBSTANCES CONTROL ACT:INVENTORY STATUSThe chemical substances in this product are on the TSCA Section 8 Inventory.EXPORT NOTIFICATIONThis product contains the following chemical substances subject to the reporting requirements of TSCA 12(B) if exported from the United States:NoneUnder HazCom 2012 it is optional to continue using the HMIS rating system. It is important to ensure employees have been trained to recognize the different numeric ratings associated with the HazCom 2012 and HMIS schemes.HMIS RATINGS - HEALTH: 2* FLAMMABILITY: 1 PHYSICAL HAZARD: 1* - Indicates a chronic hazard; see Section 2Revision: Company LogoEffective Date: 11/18/2020The information contained herein is, to the best of our knowledge and belief, accurate. However, since the conditions of handling and use are beyond our control, we make no guarantee of results, and assume no liability for damages incurred by use of this material. It is the responsibility of the user to comply with all applicable federal, state and local laws and regulations.。

芯片质量 Tadiran Batteries 非可重充式锂酯电池信息表说明书

SDS No.- T-36-04 (Revision–M)Lithium Battery Information Sheet1.Section 1: IdentificationProducts Name: Primary (non-rechargeable) Lithium metal Thionyl Chloride (Li/SOCl2) cells and batteries. Cells include the models of TL, TLH, and TLL, 3.6V series. This Battery Information Sheet covers the the above models: 2100, 2134, 2135, 2137, 2150, 2155, 2186, 2200, 2300, 2450, 4902, 4903, 4920, 4930, 4934, 4935, 4937, 4940, 4951, 4955, 4986, 5101, 5104, 5113, 5114, 5134, 5135, 5137, 5151, 5155, 5186, 5233, 5242, 5276, 5293, 5315, 5902, 5903, 5920, 5930, 5934, 5935, 5937, 5940, 5955, 5323, 7902, 7955, 7903, 7920, 7930, 7937, 8902, 8955, 8903, 8920, 8930, and 8937 with all their finishing versions and batteries assembled from them, denoted by “/” followed by letters or digits.Manufacturer Name: Tadiran Batteries Ltd., P. O. Box 1, Kiryat Ekron, Israel 70500.US office address: 2001 Marcus Avenue, Suite 125E, Lake Success, NY 11040 Emergency Telephone No: CHEMTREC: 1-800-424-9300Tel. for information: 1-516-621-4980Tel. for information 972-8-944-45032.The Lithium Thionyl chloride batteries described in this Battery Information Sheet are hermetically sealed units, which are not hazardous when used according to the recommendations of the manufacturer.Under normal condition of use of the batteries, the electrode materials and the liquid electrolyte they contained are non-reactive provided the battery integrity is maintained. Risk of exposure exists only in case of mechanical, electrical or thermal abuse. Thus the batteries should not short circuit, recharge, puncture, incinerate, crush, immerse in water, force discharge, or expose to temperatures above the temperature range of the cell or battery. In these cases there is risk of fire or explosion.Protection from charging:Whenever lithium batteries are not the single power source in a circuit, Whenever lithium batteries are not the single power source in a circuit, the measures recommended by Underwriters Laboratories are relevant. The relevant protection means should be recommended/approved by TADIRAN.* TLV- Threshold Limit Value is personal exposure limits determined by ACGIH (American Council of Governmental Industrial Hygienists).IMPORTANT NOTE: The above levels are not anticipated under normal use conditions.4.Section 4: First aid measuresIn case of battery rupture, explosion, or major leakage, evacuate personnel from contaminated area and provide good ventilation to clear out corrosive fumes, gases or the pungent odor. Seek immediate medical attention.Eyes - First rinse with plenty of water for 15 minutes (remove contact lenses if easily possible), and then seek medical attention.Skin - Remove contaminated clothes and rinse skin with plenty of water or shower for 15 min. Refer to medical attention.Inhalation - Remove to fresh air, rest, and half-upright position, use artificial respiration if needed, and refer to medical attention.Ingestion - rinse mouth, DO NOT induce vomiting, give plenty of water to drink, and refer to medical attention.5.Section 5: Fire - fighting measuresFLASH POINT: NA LOWER (LEL): NA FLAMMABLE LIMIT IN AIR: NA UPPER (LEL): NA EXTINGUISHING MEDIA:1. Lith- X (Class D extinguishing media) is the only effective on fires involving a few lithium batteries. If the cells are directly involved in a fire DO NOT USE: WATER, SAND, CO2, HALON, and DRY POWDER OR SODA ASH EXTINGUISHERS.2. If the fire is in adjacent area and the cells that are either packed in their original containers or unpacked, the fire can be fought based on fueling material, e.g., paper and plastic products. In these cases the use of copious amounts of cold water is effective extinguishing media. Storage area may also employ sprinkler system with cold water.AUTO-IGNITION: NASPECIAL FIRE FIGHTING PROCEDURES: Wear self-contained breathing apparatus to avoid breathing of irritant fumes (NIOSH approved SCBA & full protective equipment). Wear protective clothing and equipment to prevent body contact with electrolyte solution.Fire may be fought, but only from safe fire-fighting distance. Evacuate all persons from immediate area of fire.UNUSUAL EXPLOSION AND FIRE EXPLOSION: Battery may explode when subject to: excessive heat (above 150⁰C), recharged, over-discharged (discharge below 0V), punctured and crushed. During thermal decomposition generation of chlorine (Cl2), hydrogen chloride (HCl), and sulfur dioxide (SO2) can be formed.6.PROCEDURES TO CONTAIN AND CLEAN UP LEAKS OR SPILLS: The material contained within the battery would only be released under abusive conditions.In the event of battery rapture and leakage: contain the spill while wearing proper protective clothing and ventilate the area. Then, cover with sodium carbonate (Na2CO3) or 1:1 mixture of soda ash and slaked lime. Keep away from water, rain, and snow. Placed in approved container (after cooling if necessary) and disposed according to the local regulations. NEUTRALIZING AGENTS: Sodium carbonate (Na2CO3) or 1:1 mixture of soda ash and slaked lime. WASTE DISPOSAL METHOD: Product decomposed by water must be neutralized. if sufficiently diluted, it may be added to waste water if it is sufficiently diluted.PRECAUTIONS IN HANDLING AND STORAGE: avoid short-circuiting, over-charging and heating to high temperatures. Store the batteries in dry and cool area and keep container dry and tightly closed in well-ventilated area. Store cells away from food and drink.OTHER PRECAUTIONS; Never attempt to disassemble, machine, or otherwise modify batteries or injury may result.7.The batteries should not be opened, destroyed or incinerate, since they may leak or rupture and release to the environment the ingredients that they normally contained in the hermetically sealed container.HANDLING- Do not short circuit terminals, or expose to temperatures above the temperature rating of the battery, over charge the battery, forced over-discharge (voltage below 0.0V), throw to fire.Do not crush or puncture the battery, or immerse in liquids.STORAGE- is preferably done in cool (below 30⁰C), dry and ventilated area, which is subject to little temperature change.Do not place the battery near heating equipment, nor expose to direct sunlight for long periods. Elevated temperatures can result in shortened battery life and degrade performance.Keep batteries in original packaging until use and do not jumble them.Do not store batteries in high humidity environment for long periods.OTHER- cells and batteries are not rechargeable batteries and should not be charged. Applying pressure and deforming the battery may lead to disassembly followed by eye skin and throat irritation.Follow manufacturer recommendations regarding maximum recommended current and operating temperature range.GENERAL- The following safety measures are not necessary in normal use. They need only be applied if there is a risk that, in use or handling, the recommendations, as outlined in Section 3, have not been followed.RESPIRATORY PROTECTION: In case of abuse or leak of liquid or fumes, use NIOSH approved Acid Gas Filter Mask or Self-Contained Breathing Apparatus.VENTILATION: In case of abuse, use adequate mechanical ventilation (local exhaust) for battery that vents gas or fumes.PROTECTIVE GLOVES: In case of spill use PVC or Nitrile gloves of 15 mils (0.015 inch) or thicker. EYE PROTECTION: Use ANSI approved chemical worker safety goggles or face shield.OTHER PROTECTIVE EQUIPMENT: In case needed, chemical resistance clothing is recommended along with eye wash station and safety shower should be available meeting ANSI design criteria. WORK HYGIENIC PRACTICES: Use good hygiene practice. Wash hands after use and before drinking, eating or smoking. Launder contaminated cloth before reuse. SUPPLEMENTARY SAFETY AND HEALTH DATA: If the battery is broken or leaked the main hazard is the electrolyte. The electrolyte is mainly solution of Lithium chloride (LiCl), and aluminum chloride (AlCl3) in Thionyl chloride (SOCl2).Fires may be fought but only from safe fire fighting distance, evacuate all persons from immediate area of fire. Prevent heating of the battery, charging the battery, discharge to predetermined limit, do not crush, disassemble, incinerate or short circuit.9.Section 9: Physical and chemical propertiesBoiling point (760 mm Hg) NA, unless individual components exposed Vapor Pressure (mm Hg, 25ºC) NA, unless individual components exposed Vapor Density (air=1) NA, unless individual components exposed Density (gr/cc) > 1 gr/ccVolatile by Volume (%) NAEvaporation Rate (butyl acetate=1) NA, unless individual components exposed Physical State SolidSolubility in Water (% by weight) NA, unless individual components exposed PH NA, unless individual components exposed Appearance Geometric Solid ObjectOdor If leaking, gives off pungent corrosive odor10.Section 10: Stability and reactivitySTABLE OR NOT STABLE StableINCOMPATIBILITY (MATERIAL TO AVOID) Strong mineral acids, water and alkali solutions.HAZARDOUS DECOMPOSITION PRODUCTS 1. Reaction of lithium with water: Hydrogen (H2), Lithium hydroxide (LiOH).2. Thermal decomposition over 150⁰C: Sulfur oxides, (SO2, SO3), Sulfur chlorides (SCl2, S2Cl2), Chlorine (Cl2), Lithium oxide, Li2O3. Electrolyte with water: Hydrogen Chloride (HCl) and SO2DECOMPOSITION TEMPERATURE (⁰F) NAHAZARDOUS POLYMERIZATION: May Occur____ Will Not Occur __X__ CONDITIONS TO AVOID Avoid mechanical abuse and electrical abuse such as short-circuiting, overcharge, over-discharge, (voltage reversal)and heating.THRESHOLD LIMIT VALUE (TLV) AND SOURCE: NAHEALTH HAZARD ACUTE AND CHRONIC: Inhalation, skin contact, eye contact and ingestion are not likely by exposure to sealed battery.Inhalation, skin contact and eye contact are possible when the battery is opened. Exposure to internal contents, the corrosive fumes will be very irritating to skin, eyes and mucous membranes. Overexposure can cause symptoms of non-fibrotic lung injury and membrane irritation.Carcinogenicity- NTP: NoCarcinogenicity- IARC: NoCarcinogenicity- OSHA: NoExplanation of Carcinogenicity- No ingredient of a concentration of 0.1% or greater is listed as a carcinogen or suspected carcinogen.SIGNS AND SYMPTOMS OF OVEREXPOSURE: Exposure to leaking electrolyte from ruptured or leaking battery can cause:For further information refer to section 4.12.Section 12: Ecological information1.When properly used or disposed the battery does not present environmental hazard.2.Cells do not contain mercury, cadmium, lead or other heavy metals.3.Do not let internal components enter marine environment. Avoid release to waterways,wastewater or ground water.13.Section 13: Disposal Considerations4.Dispose in accordance with the applicable regulations in country and state.5.Disposal should be performed by permitted, professional disposal firms knowledgeable inFederal, State or Local requirements of hazardous waste treatment and hazardous waste transportation.6.Incineration should never be performed by battery users, but eventually by trainedprofessional in authorized facility with proper gas and fume treatment.7.Battery recycling should be done in authorized facility.14.Section 14: Transport informationShipping name:UN 3090: Lithium Metal Cells and BatteriesUN 3091: Lithium Metal Cells and Batteries contained in equipment, orLithium Metal Cells and Batteries packed with equipmentShipping information: the cells and batteries have passed successfully the tests defined in “UN Manual of Tests and Criteria”, Section 38.3 (the UN tests). The cells and batteries must be packed in accordance with Packing Instructions / Special Provisions (SP) of the applicable code, e.g., IATA (57th revised edition)/ICAO (Packing Instructions: PI968, PI969 and PI970), IMDG Code (SP188) and ADR (SP188). When required, reference shall be made to UN number 3090 (lithium ion batteries) or UN 3091 when packed with or contained in equipment.Transportation within, to and from the US: are governed by the US DOT CFR 49, Parts 171, 172, 173 and 175. They details the required packaging and labels and transportation mode of cells transported separately or in equipment. The battery cannot be shipped, within, to, and from the US by passenger aircraft. Air shipments of cells can be done only by cargo aircraft.Hazard Classification: Class 9Packing Group: N/ABattery label: Identification and labeling should be in compliance with the applicable regulations. In addition, it should also include cell/battery title, nominal voltage, lot number and warning.15.1.All the cells and batteries are defined as “articles” and thus are exempt from therequirements of the Hazard Communication Standard”.2.The internal component (Thionyl chloride) is hazardous under the criteria of the FederalOHSA Hazard Communication Standard 29 CFR 1920.1200.3.NFPA rating- Lithium batteries are not included in the NFPA material list. Below is the NFPArating for lithium metal. Lithium metal is an internal component, enclosed by hermetically sealed metallic can. Under normal application is not exposed.16.Section 16: Other informationThe information and the recommendations set forth are made in good faith and believed to be accurate at the date of preparation. The present file refers to normal use of the product in question. Tadiran Batteries makes no warranty expressed or implied.Assembly of battery packs:The design and assembly of battery packs require special skills, expertise and experience. Therefore it is not recommended that the end user will attempt to self-assemble battey packs. It is preferable that any battery using lithium cells will be assembled by TADIRAN to ensure proper battery design and construction. A full assembly service is available from TADIRAN who can be contact for further information. If for any reason, this is not possible, TADIRAN can review the pack design in confidential to ensure that the design is safe and capable of meeting the stated performance requirements.。

IFCC Aspartate Aminotransferase 检测手册说明书

ASTAspartate Aminotransferase IFCCMANUAL RX MONZAINTENDED USEFor the quantitative in vitro determination of AspartateAminotransferase (AST) in serum and plasma. This product is suitable for manual use and on the Rx Monza analyser.Cat. No. AS 1202 R1a. Buffer/Substrate 1 x 70 ml 20 x 2 ml R1b. Enzyme/Coenzyme/ 20 x 2 ml α-oxoglutarate GTIN: 05055273200416AS 1204 R1a. Buffer/Substrate 1 x 105 ml 10 x 10 ml R1b. Enzyme/Coenzyme/ 10 x 10 ml α-oxoglutarate GTIN: 05055273200423AS 1267 R1a. Buffer/Substrate 1 x 105 ml 5 x 20 ml R1b. Enzyme/Coenzyme/ 5 x 20 ml α-oxoglutarate GTIN: 05055273200430AS 2359 R1a. Buffer/Substrate 5 x 100 ml 5 x 100 ml R1b. Enzyme/Coenzyme/ 5 x 100 ml α-oxoglutarate GTIN: 05055273200454UV METHODThis is an optimised standard method according to the concentrations recommended by the IFCC.CLINICAL SIGNIFICANCE (1,2,3,4)The aminotransferases are a group of enzymes that catalyse the inter conversions of amino acids and α-oxoacids by transfer of amino groups. AST (aspartate aminotransferase or glutamate oxaloacetatetransaminase) has been found in the cytoplasm and the mitochondria of cells that have been studied. In cases of mild tissue damage, e.g. liver, the predominant form of serum AST is that from the cytoplasm, with a smaller amount coming from the mitochondria. Severe tissue damage will result in more mitochondrial enzyme being released. Elevated levels of AST can signal myocardial infarction, hepatic disease, muscular dystrophy and organ damage.Although heart muscle is found to have the most activity of the enzyme, significant activity has also been seen in the brain, liver, gastric mucosa, adipose tissue and kidneys of humans.The IFCC has now recommended (1980) standardised procedures for AST determinations including:-1. optimization of substrate concentrations.2. Employment of Tris buffers (instead of phosphate, which has beenshown to inhibit recombination of the apoenzyme with pyridoxal phosphate).3. Pre-incubation of combined buffer and serum to allow sidereactions with NADH to occur. 4. Substrate start (α-oxoglutarate)5. Optional pyridoxal phosphate activation.This is an optimised standard method according to the recommendations of the IFCC.PRINCIPLEα-oxoglutarate reacts with L-aspartate in the presence of AST to form L-glutamate plus oxaloacetate. The indicator reaction utilises the oxaloacetate for a kinetic determination of NADH consumption. AST -oxoglutarate + L-aspartate L-glutamate + oxaloacetate MDH oxaloacetate + NADH + H + L-malate + NAD +SPECIMEN COLLECTION AND PREPARATION (5) Serum:- Use serum free from haemolysis.Plasma:- EDTA or heparin can be used as the anticoagulant.Plasma should be separated from cells within one hour after collection.Specimens should be refrigerated if not used immediately:-Specimens stored longer than 3 days should be frozen at -20︒C.REAGENT COMPOSITIONContents Concentrations in the TestR1a. Buffer/Substrate Tris buffer 80 mmol/l, pH 7.5 L-aspartate 240 mmol/l R1b. Enzyme/Coenzyme/α-oxoglutarate α-oxoglutarate 12 mmol/l MDH ≥420 U/l LD ≥600 U/l NADH 0.18 mmol/lSAFETY PRECAUTIONS AND WARNINGS For in vitro diagnostic use only. Do not pipette by mouth.Exercise the normal precautions required for handling laboratory reagents.Solution R1a contains Sodium Azide. Avoid ingestion or contact with skin or mucous membranes. In case of skin contact, flush affected area with copious amounts of water. In case of contact with eyes or if ingested, seek immediate medical attention.Sodium Azide reacts with lead and copper plumbing, to form potentially explosive azides. When disposing of such reagents flush with large volumes of water to prevent azide build up. Exposed metal surfaces should be cleaned with 10% sodium hydroxide.Health and Safety data sheets available on request.The reagents must be used only for the purpose intended by suitably qualified laboratory personnel, under appropriate laboratory conditions.STABILITY AND PREPARATION OF REAGENTS R1a. Buffer/SubstrateContents ready for use. Stable up to the expiry date when stored at +2 to +8︒C.R1b. Enzyme/Coenzyme/α-oxoglutarate Reconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with the appropriate volume of Buffer/Substrate R1a: 2 ml for the 20 x 2 ml kit (AS 1202) 10 ml for the 10 x 10 ml kit (AS 1204) 20 ml for the 5 x 20 ml kit (AS 1267) Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C. Cat. AS 2359 5 x 100 mlReconstitute one vial of Enzyme/Coenzyme/α-oxoglutarate R1b with a portion of Buffer/Substrate R1a and then transfer the entire contents to bottle R1a rinsing bottle R1b several times. Stable for 14 days at +2 to +8︒C or 24 hours at +15 to +25︒C.MATERIALS PROVIDED Buffer/SubstrateEnzyme/Coenzyme/ -oxoglutarateMATERIALS REQUIRED BUT NOT PROVIDEDRandox Assayed Multisera Level 2 (Cat. No. HN 1530) and Level 3 (Cat. No. HE 1532)Randox Calibration Serum Level 3 (Cat. No. CAL 2351) RX series Saline (Cat. No. SA 3854)PROCEDUREAspirate fresh ddH 2O and perform a new Gain Calibration in flow cell mode. Select AST in the Run Test screen and carry out a water blank as instructed.Pipette into a test tube:Sample 0.05 ml Reagent 0.5 mlMix and aspirate into the Rx Monza.CALIBRATION FOR RX MONZAThe use of Saline and Randox Calibration Serum Level 3 isrecommended for calibration. Calibration is recommended with change of reagent lot or as indicated by quality control procedures.FOR MANUAL USEWavelength: 340 nm (Hg 334 nm or Hg 365 nm) Cuvette: 1 cm light path Temperature: 25/30/37︒C Measurement: against airPipette into cuvette: Macro MicroSample 0.2 ml 0.1 ml Enzyme/Coenzyme/ α-oxoglutarate R1 2.0 ml 1.0 mlMix, read initial absorbance after 1 minute. Read again after 1, 2 and 3 minutes. Note: If the absorbance change per minute is between 0.11 and 0.16 at 340/Hg 334 nm 0.06 and 0.08 at Hg 365 nmuse only the values for the first 2 minutes for the calculation.MANUAL CALCULATIONTo calculate the AST activity, use the following formulae:U/l = 1746 x A 340 nm/min U/l = 1780 x A Hg 334 nm/min U/l = 3235 x A Hg 365 nm/minSTANDARDISATIONRandox Calibration Serum Level 3 is traceable to AST reference material JSCC TS01.QUALITY CONTROLRandox Assayed Multisera, Level 2 and Level 3 are recommended for daily quality control. Two levels of controls should be assayed at least once a day. Values obtained should fall within a specified range. If these values fall outside the range and repetition excludes error the following steps should be taken:1. Check instrument settings and light source.2. Check cleanliness of all equipment in use.3. Check water. Contaminants, i.e. bacterial growth, maycontribute to inaccurate results. 4. Check reaction temperature.5. Check expiry date of kit and contents.6. Contact Randox Laboratories Customer Technical Services, Northern Ireland +44 (0) 28 9445 1070.SPECIFICITY/INTERFERENCE (6,7)Gross haemolysis will produce falsely elevated test results. The effects of various drugs on AST activity should be taken intoconsideration in the case of patients receiving large doses of drugs.The analytes below were tested up to the following levels and were found not to interfere: Haemoglobin 250 mg/dl Free Bilirubin 25 mg/dl Conjugate Bilirubin 25 mg/dl Triglycerides 1000 mg/dlIntralipid ® 200 mg/dlA list of substances and conditions known to effect AST activity in vivo is given by both Young et al and Friedman et al. Norepresentation is made by Randox Laboratories Ltd regarding the completeness of these lists and the accuracy of the information contained therein.NORMAL VALUES IN SERUM (8,9) +25︒C +30︒C +37︒C Men up to 18 U/l up to 25 U/l up to 37 U/l Women up to 15 U/l up to 21 U/l up to 31 U/lIt is recommended that each laboratory establish its own reference range to reflect the age, sex, diet and geographical location of the population.SPECIFIC PERFORMANCE CHARACTERISTICS The following performance data were obtained using an Rx Monza analyser running at +37o C.LINEARITYThis method is linear up to 562 U/l. If the sample concentration exceeds this value, dilute the sample 1+9 with 0.9% NaCl solution and re-assay. Multiply the result by 10.SENSITIVITYThe minimum detectable concentration of AST with an acceptable level of precision was determined as 9.3 U/l.PRECISIONIntra AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.66 1.47CV(%) 4.65 0.96n 20 20Inter AssayLevel 2 Level 3Mean (U/l) 35.6 153SD 1.77 7.10CV(%) 4.96 4.63n 20 20CORRELATIONThis method (Y) was compared with another commerciallyavailable method (X) and the following linear regression equationobtained:Y = 1.07X + 4.9and a correlation coefficient of r = 0.997543 patient samples were analysed spanning the range 28 to 559U/l.REFERENCES1. Wroblewski F, La Due J.S: Ann Intern Med. 1956; 45: 801.2. Wroblewski F, La Due J.S: Proc Soc Exp Biol Med 1956;91: 569.3. Bergmeyer HU, Bowers GN Jr, et al: Clin Chem 1977; 23:887.4. Bergmeyer HU, Bowers GN Jr, et al: J.Clin Chem ClinBiochem 1980; 18: 521-534.5. Tietz N W: Fundamentals of Clinical Chemistry ed 3.Philadelphia, WB Saunders Co. 1987, pg 372.6. Young D S, et al: Clin Chem 1975, 21; No5.7. Friedman RB, et al: Clin Chem 1980, 26; No4.8. Wallnofer H, Schmidt.E, Schmidt FW, eds: Synopsis derLeberkrankheiten Stuttgart, Georg Thieme Verlag, 1974.9. Thefeld W, et al: Dtsch Med Wschr 1974; 99: 343.Revised 26 Apr 16 biRev. 003THIS PAGE IS INTENTIONALLY BLANK。

Tranexamic_acid_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Tranexamic acidCatalog No. :HY-B0149CAS No. :1197-18-81.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:C8H15NO2Molecular Weight:157.21CAS No. :1197-18-84. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutant.IATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Incucyte

Product Information Presentation, Storage and StabilityThe Incucyte® Fabfluor-pH Antibody Labeling Reagents for antibody internalization are supplied as lyophilized solids in sufficient quantity to label 50 μg of test antibody, when used at the suggested molar ratio (1:3 of test antibody to labeling Fab). The lyophilized solid can be stored at 2-8° C for one year. Once re-hydrated, any unused reagent should be aliquoted and stored at -80° C for up to one year. Avoid repeated freeze-thaw cycles.Incucyte® Fabfluor-pH Antibody Labeling ReagentsFor Antibody Internalization AssaysAntibody Labeling Reagent Rehydrated: -80° C *Excitation and Emission maxima were determined at a pH of 4.5.Fabfluor_quick_guideBackgroundIncucyte ® Fabfluor-pH Antibody Labeling Reagents are designed for quick, easy labeling of Fc-containing test antibodies with a Fab fragment-conjugated pH-sensitive fluorophore. The pH-sensitive dye based system exploits the acidic environment of the lysosomes to quantify in-ternalization of the labeled antibody. As Fabfluor labeled antibodies reside in the neutral extracellular solution (pH 7.4), they interact with cell surface specific antigens and are internalized. Once in the lysosomes, they enter an acidic environment (pH 4.5–5.5) and a substantial in-crease in fluorescence is observed. In the absence of ex-pression of the specific antigen, no internalization occurs and the fluorescence intensity of the labeled antibodies remains low. With the Incucyte ® integrated analysis soft-ware, background fluorescence is minimized. These reagents have been validated for use with a number of different antibodies in a range of cell types. The Incucyte ® Live-Cell Analysis System enables real-time, kinetic eval -uation of antibody internalization.Recommended UseWe recommend that the Incucyte ® Fabfluor-pH Antibody Labeling Reagents are prepared at a stock concentration of 0.5 mg/mL by the addition of 100 μL of sterile water and triturated (centrifuge if solution not clear). The reagent may then be diluted directly into the labeling mixture with test antibody. Do NOT sonicate the solution.Additional InformationThe Fab antibody was purified from antisera by a combination of papain digestion and immunoaffinity chromatography using antigens coupled to agarose beads. Fc fragments and whole IgG molecules have been removed.Human Red (Cat. No. 4722) or Human Orange (Cat. No. 4812)—Based on immunoelectrophoresis and/ or ELISA, the antibody reacts with the Fc portion of human IgG heavy chain but not the Fab portion of human IgG. No antibody was detected against human IgM, IgA or against non-immunoglobulin serum proteins. The anti-body may cross-react with other immunoglobulins from other species.Mouse IgG1 (Cat. No. 4723), IgG2a (Cat. No. 4750) or IgG2b (Cat. No. 4751)—Based on antigen-binding assay and/or ELISA, the antibody reacts with the Fc portion of mouse IgG, IgG2a or IgG2b, respectively, but not the Fab portion of mouse immunoglobulins. No antibody was detected against mouse IgM or against non–immunoglobulin serum proteins. The antibody may cross-react with other mouse IgG subclasses or with immunoglobulins from other species.Rat (Cat. No. 4737)—Based on immunoelectrophoresis and/or ELISA, the antibody reacts with the Fc portion of rat IgG heavy chain but not the Fab portion of rat IgG. No antibody was detected against rat IgM, IgA or against non-immunoglobulin serum proteins. The antibody may cross-react with other immunoglobulins from other species.A.B.C.D.R e d O b j e c t A r e a (x 105 μm 2 p e r w e l l )Time (hours)A U C x 106 (0–12 h )log [α–CD71] (g/mL)Example DataFigure 1: Concentration-dependent increase in antibody internalization of Incucyte ® Fabfluor labeled-α-CD71 in HT1080 cells. α-CD71 and mouse IgG1 isotype control were labeled with Incucyte ® Mouse IgG1 Fabfluor-pH Red Antibody Labeling Reagent. HT1080 cells were treated with either Fabfluor-α-CD71 or Fabfluor-IgG1 (4 μg/mL); HD phase and red fluorescence images were captured every 30 minutes over 12 hours using a 10X magnification. (A) Images of cells treated with Fabfluor-α-CD71 display red fluorescence in the cytoplasm (images shown at 6 h). (B) Cells treated with labeled isotype control display no cellular fluorescence. (C) Time-course of Fabfluor-α-CD71 internalization with increasing concentrations of Fabfluor-α-CD71 (progressively darker symbols). Internalization has been quantified as the red object area for each time-point. (D) Concentration response curve to Fabfluor-α-CD71. Area under the curve (AUC) values have been determined from the time-course shown in panel C (0-12 hours) and are presented as the mean ± SEM, n=3 wells.CD71-FabfluorIgG-FabfluorProtocols and ProceduresMaterialsIncucyte® Fabfluor-pH Antibody Labeling ReagentTest antibody of interest containing human, mouse, or rat IgG Fc region (at known concentration)Target cells of interestTarget cell growth mediaSterile distilled water96-well flat bottom microplate (e.g. Corning Cat. No. 3595) for imaging96-well round black round bottom ULA plate (e.g. Corning Cat. No. 45913799) or amber microtube (e.g. Cole Parmer Cat. No. MCT-150-X, autoclaved) for conjugation step0.01% Poly-L-Ornithine (PLO) solution (e.g. Sigma Cat. No. P4957), optional for non-adherent cells Recommended control antibodiesIt is strongly recommended that a positive and negative control is run alongside test antibodies and cell lines. For example, CD71, which is a mouse anti-human antibody, is recommended as a positive control for the mouse Fab.Anti-CD71, clone MEM-189, IgG1 e.g. Sigma Cat. No. SAB4700520-100UGAnti-CD71, clone CYG4, IgG2a e.g. BioLegend Cat. No. 334102Isotype controls, depending on isotype being studied—Mouse IgG1, e.g. BioLegend Cat. No. 400124, Mouse IgG2a e.g. BioLegend Cat. No. 401501Preparation of Incucyte® Antibody Internalization Assay 1. Seed target cells of interest1.1 Harvest cells of interest and determine cell concentra-tion (e.g. trypan blue + hemocytometer).1.2 Prepare cell seeding stock in target cell growth mediawith a cell density to achieve 40–50% confluence be-fore the addition of labeled antibodies. The suggested starting range is 5,000–30,000 cells/well, although the seeding density will need to be optimized for each cell type.Note: For non-adherent cell types, a well coating may be required to maintain even cell distribution in the well. For a 96-well flat bottom plate, we recommend coating with 50 μL of either 0.01% Poly-L-Or-nithine (PLO) solution or 5 μg/mL fibronectin diluted in 0.1% BSA.Coat plates for 1 hour at ambient temperature, remove solution from wells and then allow the plates to dry for 30-60 minutes prior to cell addition.1.3 Using a multi-channel pipette, seed cells (50 µL perwell) into a 96-well flat bottom microplate. Lightly tapplate side to ensure even liquid distribution in well. Toensure uniform distribution of cells in each well, allowthe covered plate sit on a level surface undisturbed at room temperature in the tissue culture hood for 30minutes. After cells are settled, place the plate insidethe Incucyte® Live-Cell Analysis System to monitor cell confluence.Note: Depending on cell type, plates can be used in assay once cells have adhered to plastic and achieved normal cell morphology e.g.2-3 hours for HT1080 or 1-2 hours for non-adherent cell types. Some cell types may require overnight incubation.2. Label Test Antibody2.1 Rehydrate the Incucyte® Fabfluor-pH Antibody Label-ing Reagent with 100 µL sterile water to result in a final concentration of 0.5 mg/mL. Triturate to mix (centrifuge if solution is not clear).Note: The reagent is light sensitive and should be protected fromlight. Rehydrated reagent can be aliquoted into amber or foilwrapped tubes and stored at -80° C for up to 1 year (avoid freezing and thawing).2.2 Mix test antibody with rehydrated Incucyte® Fabfluor–pH Antibody Labeling Reagent and target cell growth media in a black round bottom microplate or ambertube to protect from light (50 µL/well).a. Add test antibody and Incucyte® Fabfluor–pH Anti-body Labeling Reagent at 2X the final concentration.We suggest optimizing the assay by starting with afinal concentration of 4 µg/mL of test antibody or theFabfluor-pH Antibody Labeling Reagent (i.e. 2Xworking concentration = 8 µg/mL).Note: A 1:3 molar ratio of test antibody to Incucyte® Fabfluor-pHAntibody Labeling Reagent is recommended. The labeling re-agent is a third of the size of a standard antibody (50 and 150KDa, respectively). Therefore, labeling equal quantities will pro-duce a 1:3 molar ratio of test antibody to labeling Fab.b. Make sufficient volume of 2X labeling solution for50 µL/well for each sample. Triturate to mix.c. Incubate at 37° C for 15 minutes protected from light.Note: If performing a range of concentrations of test antibody,e.g. concentration response-curve, it is recommended to createthe dilution series post the conjugation step to ensure consistentmolar ratio. We strongly recommend the use of both a negativeand positive control antibody in the same plate.3. Add labeled antibody to cells3.1 Remove cell plate from incubator.3.2 Using a multi-channel pipette, add 50 µL of 2X labeledantibody and control solutions to designated wells.Remove any bubbles and immediately place plate in the Incucyte® Live-Cell Analysis System and start scanning.Note: To reduce the risk of condensation formation on the lid priorto first image acquisition, maintain all reagents at 37° C prior toplate addition.4. Acquire images and analyze4.1 In the Incucyte® Software, schedule to image every15-30 minutes, depending on the speed of the specific antibody internalization.a Scan on schedule, standard. If the Incucyte® Cell-by-Cell Analysis Software Module (Cat. No. 9600-0031)is available, adherent cell-by-cell or non-adherentcell-by-cell scan types can be selected.b Channel selection: select “phase” and “red” or“phase” and "orange” (depending on reagent used).c Objective: 10X or 20X depending on cell types used,generally 10X is recommended for adherent cells,and 20X for non-adherent or smaller cells.NOTE: The optional Incucyte® Cell-by-Cell Analysis SoftwareModule enables the classification of cells into sub-populationsbased on properties including fluorescence intensity, size andshape. For further details on this analysis module and its appli-cation, please see: /cell-by-cell.4.2 To generate the metrics, user must create an AnalysisDefinition suited to the cell type, assay conditions andmagnification selected.4.3 Select images from a well containing a positiveinternalization signal and an isotype control well(negative signal) at a time point where internalizationis visible.4.4 In the Analysis Definition:Basic Analyzer:a. Set up the mask for the phase confluence measurewith fluorescence channel turned off.b. Once the phase mask is determined, turn the fluores-cence channel on: Exclude background fluorescencefrom the mask using the background subtractionfeature. The feature “Top-Hat” will subtract localbackground from brightly fluorescent objects withina given radius; this is a useful tool for analyzing ob-jects which change in fluorescence intensity overtime.i The radius chosen should reflect the size of thefluorescent object but contain enough backgroundto reliably estimate background fluorescence inthe image; 20-30 μm is often a useful startingpoint.ii The threshold chosen will ensure that objectsbelow a fluorescence threshold will not bemasked.iii Choose a threshold in which red or orange objectsare masked in the positive response image but lownumbers in the isotype control, negative responsewell. For a very sensitive measurement, for example,if interested in early responses, we suggest athreshold of 0.2.NOTE: The Adaptive feature can be used for analysis but maynot be as sensitive and may miss early responses. If interestedin rate of response, Top-Hat may be preferable.Cell-by-Cell (if available):a. Create a Cell-by-Cell mask following the softwaremanual.b. There is no need to separate phase and fluorescencemasks. The default setting of Top-Hat No Mask forthe fluorescence channel will enable backgroundsubtraction without generation of a mask. Ensurethat the Top-Hat radius is set to a value higher thanthe radius of the larger clusters to avoid excess back-ground subtraction.c. The threshold of fluorescence can be determined inCell-by-Cell Classification.Specifications subject to change without notice.© 2020. All rights reserved. Incucyte, Essen BioScience, and all names of Essen BioScience prod -ucts are registered trademarks and the property of Essen BioScience unless otherwise specified. Essen BioScience is a Sartorius Company. Publication No.: 8000-0728-A00Version 1 | 2020 | 04Sales and Service ContactsFor further contacts, visit Essen BioScience, A Sartorius Company /incucyte Sartorius Lab Instruments GmbH & Co. KGOtto-Brenner-Strasse 20 37079 Goettingen, Germany Phone +49 551 308 0North AmericaEssen BioScience Inc. 300 West Morgan Road Ann Arbor, Michigan, 48108USATelephone +1 734 769 1600E-Mail:***************************EuropeEssen BioScience Ltd.Units 2 & 3 The Quadrant Newark CloseRoyston Hertfordshire SG8 5HLUnited KingdomTelephone +44 (0) 1763 227400E-Mail:***************************APACEssen BioScience K.K.4th floor Daiwa Shinagawa North Bldg.1-8-11 Kita-Shinagawa Shinagawa-ku, Tokyo 140-0001 JapanTelephone: +81 3 6478 5202E-Mail:*************************5. Analysis GuidelinesAs the labeled antibody is internalized into the acidic environment of the lysosome, the area of fluorescence intensity inside the cells increases.This can be reported in two ways:Ways to Report Basic AnalyzerCell-by-Cell Analysis* To correct for cell proliferation, it is advisable to normalize the fluorescence area to the total cell area using User Defined Metrics.For Research Use Only. Not For Therapeutic or Diagnostic Use.LicensesFor non-commercial research use only. Not for therapeutic or in vivo applications. Other license needs contact Essen BioS cience.Fabfluor-pH Red Antibody Labeling Reagent: This product or portions thereof is manufactured under license from Carnegie Mellon University and U.S. patent numbers 7615646 and 8044203 and related patents. This product is licensed for sale only for research. It is not licensed for any other use. There is no implied license hereunder for any commercial use.Fabfluor-pH Orange Antibody Labeling Reagent: This product or portions thereof is manufactured under a license from Tokyo University and is covered by issued patents EP2098529B1, JP5636080B2, US8258171, and US9784732 and related patent applications. This product and related products are trademarks of Goryo Chemical. Any application of above mentioned technology for commercial purpose requires a separate li -cense from: Goryo Chemical, EAREE Bldg., SF Kita 8 Nishi 18-35-100, Chuo-Ku, Sapporo, 060-0008 Japan.SupportA complete suite of cell health applications is available to fit your experimental needs. Find more information at /incucyte Foradditionalproductortechnicalinformation,************************************************************/incucyte。

异壬酸 INA Oxea CN

饱和蒸气压
价值 [hPa] 0,0046 4,5
密度
@ °C 20 50
@ °F 68 122
_____________________________________________________________________________________________
5 / 10
中国 (ICN)/CN
其它危险
在加强热时蒸气/空气混合物是爆炸性的。
第三部分成分/组成信息
化学名异壬酸
化学文摘编号(CAS No。) 3302-10-1
EINECS 号码 221-975-0
备注 Mixture of isomeric Isononanoic acids, mainly 3,5,5-Trimethylhexanoic acid.
Product Stewardship FAX: +49 (0)208 693 2053 email: psq@
+86 10 5100 3039 (中国)
第二部分危险性概述
分类基础
分类
急性口服中毒急性皮肤中毒皮肤腐蚀/刺激严重眼损伤 / 眼刺激环境危害
危险标记
0,876
@ °C 20
50
@ °F 68
122
方法德国工业标准 (DIN)51757 德国工业标准 (DIN)51757
折射率粘度
方法 PH值水溶性辛醇--水的分配系数的对数值表面张力
1,429 @ 20 °C 10 - 12 mPa*s @ 20 °C DIN 51562, 动态 4,4 (0,1 克/升在水中 @ 20 °C (68 °F)) 0,7 g/l @ 20 °C, OECD 105 3,2 (实测), OECD 117 35,3 mN/m (0,63 g/l @ 20°C), OECD 115

氨甲环酸片-日本

1193 JP XV O‹cial Monographs/Tranexamic Acid Tabletsof tranexamic acid(C8H15NO2),add30mL of water,shake well,and add water to make exactly50mL.Centrifuge,ˆlter the supernatant liquid through a membraneˆlter with pore size of not more than0.45m m,discard theˆrst10mL of the ˆltrate,and use the subsequentˆltrate as the sample solution. Separately,weigh accurately about50mg of Tranexamic Acid Reference Standard,previously dried at1059C for2 hours,dissolve in water to make exactly25mL,and use this solution as the standard solution.Perform the test with ex-actly30m L each of the sample solution and standard solution as directed under Liquid Chromatography<2.01>according to the following conditions,and determine the peak areas,A T and A S,of tranexamic acid.Amount(mg)of tranexamic acid(C8H15NO2)＝W S×(A T/A S)×2W S:Amount(mg)of Tranexamic Acid Reference Standard Operating conditions—Detector,column,and mobile phase:Proceed as directed in the operating conditions in the Assay under Tranexamic Acid.Column temperature:A constant temperature of about 359C.Flow rate:Adjust the‰ow rate so that the retention time of tranexamic acid is about16minutes.System suitability—System performance:To5mL of the standard solution add1mL of a solution of4-(aminomethyl)benzoic acid(1in 10,000)and water to make50mL.When the procedure is run with30m L of this solution under the above operating condi-tions,tranexamic acid and4-(aminomethyl)benzoic acid are eluted in this order with the resolution between these peaks being not less than3.System repeatability:When the test is repeated6times with 30m L of the standard solution under the above operating conditions,the relative standard deviation of the peak area of tranexamic acid is not more than1.0z.Containers and storage Containers—Tight containers. Tranexamic Acid Injectionトラネキサム酸注射液Tranexamic Acid Injection is an aqueous injection.It contains not less than95.0z and not more than 105.0z of the labeled amount of tranexamic acid (C8H15NO2:157.21).Method of preparation Prepare as directed under Injections,with Tranexamic Acid.Description Tranexamic Acid Injection is a clear and color-less liquid.Identiˆcation To a volume of Tranexamic Acid Injection, equivalent to50mg of Tranexamic Acid according to the labeled amount,add water to make5mL,add1mL of ninhydrin TS,and heat:a dark purple color develops.pH<2.54>7.0–8.0Bacterial endotoxins<4.01>Not more than0.12EU/mg. Extractable volume<6.05>It meets the requirement.Foreign insoluble matter<6.06>Perform the test according to Method1:it meets the requirement.Insoluble particulate matter<6.07>Perform the test accord-ing to Method1:it meets the requirement.Sterility<4.06>Perform the test according to the Membrane ˆltration method:it meets the requirement.Assay Take accurately a volume of Tranexamic Acid Injection,equivalent to about0.1g of tranexamic acid (C8H15NO2),add water to make exactly50mL,and use this solution as the sample solution.Separately,weigh accurately about50mg of Tranexamic Acid Reference Standard, previously dried at1059C for2hours,dissolve in water to make exactly25mL,and use this solution as the standard so-lution.Perform the test with exactly30m L each of the sample solution and standard solution as directed under Liquid Chromatography<2.01>according to the following conditions,and determine the peak areas,A T and A S,of tranexamic acid.Amount(mg)of tranexamic acid(C8H15NO2)＝W S×(A T/A S)W S:Amount(mg)of Tranexamic Acid Reference StandardOperating conditions—Detector,column,and mobile phase:Proceed as directed in the operating conditions in the Assay under Tranexamic Acid.Column temperature:A constant temperature of about 359C.Flow rate:Adjust the‰ow rate so that the retention time of tranexamic acid is about16minutes.System suitability—System performance:To5mL of the standard solution add1mL of a solution of4-(aminomethyl)benzoic acid(1in 10,000)and water to make50mL.When the procedure is run with30m L of this solution under the above operating condi-tions,tranexamic acid and4-(aminomethyl)benzoic acid are eluted in this order with the resolution between these peaks being not less than3.System repeatability:When the test is repeated6times with 30m L of the standard solution under the above operating conditions,the relative standard deviation of the peak area of tranexamic acid is not more than1.0z.Containers and storage Containers—Hermetic containers. Tranexamic Acid Tabletsトラネキサム酸錠Tranexamic Acid Tablets contain not less than 95.0z and not more than105.0z of the labeled amount of tranexamic acid(C8H15NO2:157.21).Method of preparation Prepare as directed under Tablets, with Tranexamic Acid.Identiˆcation To an amount of powdered Tranexamic Acid Tablets,equivalent to0.5g of Tranexamic Acid according to the labeled amount,add50mL of water,shake well,and ˆlter.To5mL of theˆltrate add1mL of ninhydrin TS,and1194JP XVTrapidil /O‹cial Monographsheat for 3minutes:a dark purple color develops.Uniformity of dosage units <6.02>It meets the requirementof the Mass variation test.DissolutionBeing specified separately.Assay Weigh accurately the mass of not less than 20Tranexamic Acid Tablets,and powder.Weigh accurately a quantity of the powder,equivalent to about 5g of tranexamic acid (C 8H 15NO 2),add 150mL of water,disintegrate the tablets completely with the aid of ultrasonic waves,and add water to make exactly 200mL.Centrifuge,pipet 4mL of the supernatant liquid,and add water to make exactly 50mL.Filter through a membrane ˆlter with pore size of not more than 0.45m m,discard the ˆrst 10mL of the ˆltrate,and use the subsequent ˆltrate as the sample solution.Separately,weigh accurately about 50mg of Tranexamic Acid Reference Standard,previously dried at 1059C for 2hours,dissolve in water to make exactly 25mL,and use this solution as the standard solution.Perform the test with exactly 30m L each of the sample solution and standard solution as directed un-der Liquid Chromatography <2.01>according to the follow-ing conditions,and determine the peak areas,A T and A S ,of tranexamic acid.Amount (mg)of tranexamic acid (C 8H 15NO 2)＝W S ×(A T /A S )×100W S :Amount (mg)of Tranexamic Acid Reference Standard Operating conditions —Detector,column,and mobile phase:Proceed as directed in the operating conditions in the Assay under Tranexamic Acid.Column temperature:A constant temperature of about 359C.Flow rate:Adjust the ‰ow rate so that the retention time of tranexamic acid is about 16minutes.System suitability —System performance:To 5mL of the standard solution add 1mL of a solution of 4-(aminomethyl)benzoic acid (1in 10,000)and water to make 50mL.When the procedure is run with 30m L of this solution under the above operating condi-tions,tranexamic acid and 4-(aminomethyl)benzoic acid are eluted in this order with the resolution between these peaks being not less than 3.System repeatability:When the test is repeated 6times with 30m L of the standard solution under the above operating conditions,the relative standard deviation of the peak area of tranexamic acid is not more than 1.0z .Containers and storageContainers—Tight containers.TrapidilトラピジルC 10H 15N 5:205.267-Diethylamino-5-methyl[1,2,4]triazolo[1,5-a ]pyrimidine[15421-84-8]Trapidil,when dried,contains not less than 98.5z of C 10H 15N 5.Description Trapidil occurs as a white to pale yellowish white,crystalline powder.It is very soluble in water and in methanol,freely soluble in ethanol (95),in acetic anhydride and in acetic acid (100),and sparingly soluble in diethyl ether.The pH of a solution of Trapidil (1in 100)is between 6.5and 7.5.Identification (1)To 5mL of a solution of Trapidil (1in 50)add 3drops of Dragendorff's TS:an orange color de-velops.(2)Determine the absorption spectrum of a solution of Trapidil (1in 125,000)as directed under Ultraviolet-visible Spectrophotometry <2.24>,and compare the spectrum with the Reference Spectrum:both spectra exhibit similar intensi-ties of absorption at the same wavelengths.Absorbance <2.24>E 1z1cm (307nm):860–892(after drying,20mg,water,2500mL).Melting point <2.60>101–1059CPurity (1)Clarity and color of solution—Dissolve 2.5g of Trapidil in 10mL of water:the solution is clear and colorless to pale yellow.(2)Chloride <1.03>—Perform the test with 0.5g of Trapidil.Prepare the control solution with 0.25mL of 0.01mol W L hydrochloric acid VS (not more than 0.018z ).(3)Ammonium—Place 0.05g of Trapidil in a glass-stop-pered conical flask,thoroughly moisten with 10drops of so-dium hydroxide TS,and stopper the flask.Allow it to stand at 379C for 15minutes:the gas evolved does not change moistened red litmus paper to blue.(4)Heavy metals <1.07>—Dissolve 1.0g of Trapidil in 40mL of water,and add 1.5mL of dilute hydrochloric acid,2mL of dilute acetic acid and water to make 50mL.Perform the test using this solution as the test solution.Prepare the control solution as follows:to 1.0mL of Standard Lead So-lution add 2mL of dilute acetic acid and water to make 50mL (not more than 10ppm).(5)Arsenic <1.11>—Prepare the test solution with 1.0g of Trapidil according to Method 1,and perform the test (not more than 2ppm).(6)Related substances—Dissolve 0.10g of Trapidil in 4mL of methanol,and use this solution as the sample solution.Pipet 1mL of the sample solution,and add methanol to make exactly 20mL.Pipet 1mL of this solution,add methanol to make exactly 100mL,and use this solution as the standard solution.Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>.Spot 20m L each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography.Develop the plate with a mixture of chloroform,ethanol (95)and acetic acid (100)(85:13:2)to a distance of about 10cm,and air-dry the plate.Allow the plate to stand in iodine vapor for 60minutes:the spots other than the principal spot from the sample solution are not more intense than the spot from the standard solution.Loss on drying <2.41>Not more than 0.5z (1g,in vacuum,silica gel,609C,3hours).。

氨甲环酸

氨甲环酸
氨甲环酸
【拉丁名】
Tranexamic Acid
【CAS号】
1197-18-8
【别名】止血环酸，凝血酸。

【作用和用途】
与止血芳酸相似。

用于各种出血性疾病，手术时异常出血等。

【主要成分】氨甲环酸。

【药理作用】低剂量能抑制纤溶酶原的活化作用。

高剂量还能直接抑制纤溶酶的蛋白溶解酶的活性，也能抑制胰蛋白酶、糜蛋白酶的活性。

本品与纤溶酶原或纤溶酶的赖氨酸结合区有高度亲和力，故能竞争性抑制纤维蛋白的赖氨酸与纤溶酶结合，从而抑制纤维蛋白凝块的裂解，产生止血作用。

【适应证】治疗纤溶亢进引起的出血，如肝硬化者术中渗血。

此外也可以用于反复性鼻出血、眼外伤出血、蛛网膜下复发性出血等。

血友病患者、遗传性抗纤溶酶缺乏者拔牙前后给药，可减少输注凝血因子的用量。

【不良反应】头痛、头晕、嗜睡、恶心、呕吐、腹泻等。

【禁忌证】有血栓形成倾向病人禁用。

【用法用量】口服：0．25～0．5g/次，3～4次/日。

【注意事项】①心、肝、肾功能损害者减量或慎用。

②上泌尿道出血者慎用，因有引起肾小球毛细血管血栓的可能性。

③不宜用于前列腺或尿道手术的止血药。

④该类药物不宜用于治疗活跃的血管内凝血或纤维蛋白沉积的患者，因有加重血栓栓塞的危险，也不宜用于弥漫性血管内凝血患者。

⑤若纤溶十分明显，应用时应小心监测。

⑥持续应用本品者，应作视力、视野及眼底检查。

全球化妆品法规中祛斑美白类产品的相关规定

91中国食品药品检定研究院，北京　100050…………………………黄湘鹭　刘　敏　邢书霞#　孙　磊全球化妆品法规中祛斑美白类产品的相关规定梳理全球范围内主要的化妆品生产国家和地区关于祛斑美白化妆品的相关法规，对祛斑美白原料管理方面所面临的挑战进行了分析并提出相关建议。

以主要的化妆品生产国家和地区为研究对象，如欧盟、美国、日本、韩国和中国台湾地区，通过对不同国家及地区的化妆品分类界定、管理方式进行研究比对，并结合我国目前的祛斑美白原料管理现状和问题，提出适合我国国情的监管建议。

祛斑　美白　化妆品　监管Mandatory Regulations and Standards Regarding Skin Bleaching/Whitening Products in Major Countries and RegionsHUANG Xianglu LIU Min XING Shuxia #　SUN Lei(National Institutes for Food and Drug Control, Beijing 100050, China)Abstract ：The worldwide regulations on skin bleaching/whitening cosmetics in different countries and regions were collected, the challenges faced in the management of skin bleaching/whitening ingredients were analyzed, and related suggestions were put forward. Countries and regions which are the major producers and consumers were chosen as objects, including the European Union, America, Japan, Korea and Taiwan region of China. The classiﬁcation and management of cosmetics in different countries and regions were compared. Through combing the current management status and problems of skin bleaching/whitening ingredients in China, some regulatory measures suitable for China were summarized. Keywords ：skin bleaching skin whitening cosmetics supervision作者简介黄湘鹭（1985—），女，研究生学历，硕士，助理研究员，主要从事食品、化妆品的质量控制与风险评估领域相关研究。

通驰 Flo Rite 1197 安全技术说明书

安全技术说明书页: 1/14 巴斯夫安全技术说明书按照GB/T 16483编制日期 / 本次修订: 16.05.2022版本: 2.0日期/上次修订: 18.11.2019上次版本: 1.2日期 / 首次编制: 24.11.2015产品: 通驰 Flo Rite® 1197Product: Flo Rite 1197(30587338/SDS_GEN_CN/ZH)印刷日期 16.10.20231. 化学品及企业标识通驰 Flo Rite® 1197Flo Rite 1197推荐用途和限制用途: 种子包衣公司:巴斯夫(中国)有限公司中国上海浦东江心沙路300号邮政编码 200137电话: +86 21 20391000传真号: +86 21 20394800E-mail地址: **********************紧急联络信息:巴斯夫紧急热线中心（中国）+86 21 5861-1199巴斯夫紧急热线中心（国际）:电话: +49 180 2273-112Company:BASF (China) Co., Ltd.300 Jiang Xin Sha RoadPu Dong Shanghai 200137, CHINA Telephone: +86 21 20391000Telefax number: +86 21 20394800E-mail address: ********************** Emergency information:Emergency Call Center (China):+86 21 5861-1199International emergency number: Telephone: +49 180 2273-1122. 危险性概述纯物质和混合物的分类:急性毒性: 分类5 (口服)巴斯夫安全技术说明书日期 / 本次修订: 16.05.2022版本: 2.0产品: 通驰 Flo Rite® 1197Product: Flo Rite 1197(30587338/SDS_GEN_CN/ZH)印刷日期 16.10.2023 特异性靶器官毒性-一次接触 (中枢神经系统, 视神经): 分类2标签要素和警示性说明:警示词:警告危险性说明:H303吞咽可能有害。

氨基锂-安全技术说明书MSDS

手防护：
戴防护手套。
其他防护：
无资料
第九部分：理化特性
pH：
无资料
熔点(℃)：
380～400
沸点(℃)：
430
分子式：
LiNH2
主要成分：
无资料
饱和蒸气压(kPa)：
无资料
辛醇/水分配系数的对数值：
无资料
临界温度(℃)：
无资料
闪点(℃)：
无资料
引燃温度(℃)：
无资料
自燃温度：
无资料
燃烧性：
易燃
溶解性：
第七部分：操作处置与储存
操作注意事项：
无资料
储存注意事项：
储存于高燥清洁的仓间内。远离火种、热源。相对湿度保持在75%以下。仓温不宜超过10℃。保持容器密封。注意防潮和雨水浸入。应与氧化剂、酸类、碱类分开存放。搬运时要轻装轻卸，防止包装及容器损坏。雨天搬运要妥善遮盖。
第八部分：接触控制/个体防护
中国MAC(mg/m3)：
稳定性：
稳定
禁配物：
强氧化剂、酸类、水、醇类。
避免接触的条件：
接触潮气可分解。
聚合危害：
不能出现
分解产物：
无资料
第十一部分：毒理学信息
急性毒性：
无资料
亚急性和慢性毒性：
无资料
RTECS：
OJ5590000
刺激性：
无资料
致敏性：
无资料
致突变性：
无资料
致畸性：
无资料
致癌性：
无资料
第十二部分：生态学资料
生态毒理毒性：
第八部分
接触控制和个体防护
第十六部分
其他信息
第一部分：化学品及企业标识

氨基化锂物质安全数据表MSDS

氨基化锂物质安全数据表MSDS第一部分化学品名称化学品中文名：氨基化锂化学品英文名Lithiumamide中文名称2:氨基锂英文名称2:技术说明书编码:1129CAS号:7782-89-0分子式:LiNH2分子量:22.96第二部分成分/组成信息纯品或混合物：纯品第三部分危险性概述危险性类别：第4.3类遇水放出易燃气体的物质侵入途径：健康危害：本品对粘膜、上呼吸道、眼睛及皮肤有强烈刺激性。

吸入后，可因喉和支气管的痉挛、炎症和水肿，化学性肺炎或肺水肿而致死。

中毒表现有烧灼感、咳嗽、喘息、喉炎、气短、头痛、恶心和呕吐。

环境危害：燃爆危险：本品遇湿易燃，具强刺激性。

第四部分急救措施皮肤接触：立即脱去污染的衣着，用大量流动清水冲洗。

就医。

眼睛接触：立即提起眼睑，用大量流动清水或生理盐水彻底冲洗至少15分钟。

就医。

吸入：迅速脱离现场至空气新鲜处。

保持呼吸道通畅。

如呼吸困难，给输氧。

如呼吸停止，立即进行人工呼吸。

就医。

食入：用水漱口，给饮牛奶或蛋清。

就医。

第五部分消防措施危险特性：遇明火、高热易引起燃烧爆炸。

遇水分解放热，并散发出易燃的氨气。

有害燃烧产物：氨。

灭火方法：消防人员须戴好防毒面具，在安全距离以外，在上风向灭火。

灭火剂：干粉、二氧化碳、砂土。

禁止用水和泡沫灭火。

第六部分泄漏应急处理应急处理：隔离泄漏污染区，限制出入。

切断火源。

建议应急处理人员戴自给正压式呼吸器,穿防毒服。

用砂土、干燥石灰或苏打灰混合。

小心扫起，转移至安全场所。

若大量泄漏，用塑料布、帆布覆盖。

收集回收或运至废物处理场所处置。

第七部分操作处置与储存操作注意事项：密闭操作，局部排风。

操作人员必须经过专门培训，严格遵守操作规程。

建议操作人员佩戴防尘面具(全面罩)，穿胶布防毒衣，戴橡胶手套。

远离火种、热源，工作场所严禁吸烟。

使用防爆型的通风系统和设备。

避免产生粉尘。

避免与氧化剂、酸类、醇类接触。

尤其要注意避免与水接触。

搬运时要轻装轻卸，防止包装及容器损坏。

1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。

Caution: Not fully tested. For research purposes only Medchemexpress LLC

m o c . s s e r p x e m e h c d e m . w w w : b e AW Sm U o ,c 0 . 4s 5s 8e 0r p Jx Ne ,m n e oh t c e cd ne i m r P @ o ,f y n a i Wl : ni a om s Ehanisms: Pathways:Others; Target:Others g y Biological Activity: Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Target: Tranexamic acid is a synthetic derivative of the amino acid lysine. Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Its oral form is now being evaluated for use in outpatient conditions involving heavy bleeding. Toxicity/Adverse y event: Rare in g general, including gg gastrointestinal effects, dizziness, fatigue, g headache, and hypersensitivity reactions. Use of tranexamic acid has a potential risk of thrombosis.... References: [1]. Bhat A, et al. Tranexamic acid overdosage-induced generalized seizure in renal failure. Saudi J Kidney Dis Transpl. 2014 Jan-Feb;25(1):130-2. [2]. Couturier R, et al. Continuous or discontinuous tranexamic acid effectively inhibits fibrinolysis in children undergoing g g cardiac surgery g y with cardiopulmonary p y bypass. yp Blood Coagul g Fibrinolysis. y 2014 Jan 13.
Product Data Sheet
Product Name: CAS No.: Cat. No.: MWt: Formula: Purity :
Tranexamic acid 1197-18-8 HY-B0149 157.21 C8H15NO2 >98%
Solubility:
DMSO <1 mg/ml; Water 31mg/ml